Clinical Trials Directory

Trials / Completed

CompletedNCT03354676

Adiponectin, Leptin, h-CRP Values in Obese Children - Important Markers for Metabolic Syndrome?

Status
Completed
Phase
Study type
Observational
Enrollment
122 (actual)
Sponsor
Alexandru Florin Rogobete · Academic / Other
Sex
All
Age
4 Years – 18 Years
Healthy volunteers
Not accepted

Summary

Obesity is a chronic inflammatory disorder in which leptin, adiponectin and C reactive protein (CRP) play an important role. This study aimed to investigate the relationship between markers of adiposity like leptin, adiponectin and high sensitive C reactive protein (hsCRP) in obese children, and to determine whether these adipokines are significant markers in defining metabolic syndrome in pediatric population

Detailed description

The idea that adipose tissue is just a form of energy storage has changed dramatically in recent years. Currently, adipose tissue is considered to be a true endocrine gland that fulfills multiple roles in regulating different biological functions. Communication between adipose tissue and the rest of the systems is accomplished through bioactive mediators (adipokines) Adipokines control energy homeostasis and are involved in metabolic, endocrine and immunological processes.This study aimed to investigate the relationship between markers of adiposity like leptin, adiponectin and high sensitive C reactive protein (hsCRP) in obese children, and to determine whether these adipokines are significant markers in defining metabolic syndrome in pediatric population.The current retrospective observational study was conducted at the "Louis Turcanu" Emergency Hospital Timisoara over a period of one year, from July 2013 and June 2014. All inborn patient files were analyzed as anonymised limited data sets from archived records of the Endocrinology, Diabetology and Cardiology department.

Conditions

Interventions

TypeNameDescription
OTHERMetS+Data processing from Patient Medical Files
OTHERMetS-Data processing from Patient Medical Files

Timeline

Start date
2016-03-11
Primary completion
2017-08-11
Completion
2017-09-10
First posted
2017-11-28
Last updated
2017-11-28

Source: ClinicalTrials.gov record NCT03354676. Inclusion in this directory is not an endorsement.